Biothera acquires MUC1 anti-cancer monoclonal antibody from Antisoma

2011-03-10 16:35:33

Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development. AS1402 was originally developed by CRT.

To find out more, visit the Biothera website.

Notes to editors